Literature DB >> 18311545

The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research.

Halina Ostrowska1.   

Abstract

The ubiquitin-proteasome system is responsible for the degradation of most intracellular proteins, including those that control cell cycle progression, apoptosis, signal transduction and the NF-kappaB transcriptional pathway. Aberrations in the ubiquitin-proteasome system underlie the pathogenesis of many human diseases, so both the ubiquitin-conjugating system and the 20S proteasome are important targets for drug discovery. This article presents a few of the most important examples of the small molecule inhibitors and modulators targeting the ubiquitin-proteasome system, their mode of action, and their potential therapeutic relevance in the treatment of cancer and inflammatory-related diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311545      PMCID: PMC6275582          DOI: 10.2478/s11658-008-0008-7

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  60 in total

Review 1.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 2.  Proteasome inhibitors as therapeutic agents: current and future strategies.

Authors:  J G Delcros; M Baudy Floc'h; C Prigent; Y Arlot-Bonnemains
Journal:  Curr Med Chem       Date:  2003-03       Impact factor: 4.530

Review 3.  Proteasome inhibition as novel treatment strategy in leukaemia.

Authors:  J Vink; J Cloos; G J L Kaspers
Journal:  Br J Haematol       Date:  2006-06-20       Impact factor: 6.998

4.  Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.

Authors:  Tom Van Maerken; Frank Speleman; Joëlle Vermeulen; Irina Lambertz; Sarah De Clercq; Els De Smet; Nurten Yigit; Vicky Coppens; Jan Philippé; Anne De Paepe; Jean-Christophe Marine; Jo Vandesompele
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

5.  Skp2 is oncogenic and overexpressed in human cancers.

Authors:  M Gstaiger; R Jordan; M Lim; C Catzavelos; J Mestan; J Slingerland; W Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

6.  Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.

Authors:  L Zhang; Z G Zhang; R L Zhang; M Lu; J Adams; P J Elliott; M Chopp
Journal:  Stroke       Date:  2001-12-01       Impact factor: 7.914

7.  Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.

Authors:  Joseph Pye; Farhad Ardeshirpour; Arlene McCain; Dwight A Bellinger; Elizabeth Merricks; Julian Adams; Peter J Elliott; Christine Pien; Thomas H Fischer; Albert S Baldwin; Timothy C Nichols
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11-07       Impact factor: 4.733

8.  A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats.

Authors:  David C Swinney; Yi-Zheng Xu; Liliana E Scarafia; Ina Lee; Amy Y Mak; Qing-Fen Gan; Chakkodabylu S Ramesha; Mary A Mulkins; Jim Dunn; On-Yee So; Teresa Biegel; Marie Dinh; Pamela Volkel; Jim Barnett; Stacie A Dalrymple; Simon Lee; Martin Huber
Journal:  J Biol Chem       Date:  2002-04-11       Impact factor: 5.157

Review 9.  Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases.

Authors:  M Takaoka; M Ohkita; Y Matsumura
Journal:  Curr Vasc Pharmacol       Date:  2003-03       Impact factor: 2.719

10.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Authors:  Teru Hideshima; Constantine Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; Klaus Podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

View more
  5 in total

Review 1.  Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.

Authors:  Evert Njomen; Jetze J Tepe
Journal:  J Med Chem       Date:  2019-03-14       Impact factor: 7.446

2.  Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors.

Authors:  Harshani R Lawrence; Aslamuzzaman Kazi; Yunting Luo; Robert Kendig; Yiyu Ge; Sanjula Jain; Kenyon Daniel; Daniel Santiago; Wayne C Guida; Saïd M Sebti
Journal:  Bioorg Med Chem       Date:  2010-06-18       Impact factor: 3.641

Review 3.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 4.  Ubiquitin at the crossroad of cell death and survival.

Authors:  Yu-Shan Chen; Xiao-Bo Qiu
Journal:  Chin J Cancer       Date:  2013-07-02

Review 5.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.